PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 17, 1956JAMA71 citations

Clinical Investigations on Attenuated Strains of Poliomyelitis Virus

View Full Paper
HKHilary Koprowski

Key Result

Administration of attenuated SM type 1 or TN type 2 poliomyelitis virus induced antibody development in 100% of 225 nonimmune subjects without causing acute disease or neurological manifestations.

PICO

P
Population
225 nonimmune human subjects who received attenuated strains of poliomyelitis virus for immunization purposes.
I
Intervention / Comparator
Attenuated strains of poliomyelitis virus (SM type 1 or TN type 2)
O
Primary Outcome
Antibody development

Abstract

• Alimentary infection without acute disease and without neurological manifestations was induced in two series of human subjects. In one series, SM type 1 poliomyelitis virus was given in capsules; in the other, TN type 2 virus was given in milk suspension. Altogether, 225 nonimmune subjects have received one or the other of these two viruses for immunization purposes; all have developed antibodies, and none have suffered any ill-effects that could be ascribed to the ingestion of the living poliomyelitis virus. Within the isolation unit, observations on transmissibility of the virus were made by setting up conditions that permitted contact. Transmission occurred in 5 of 15 contacts. The nurses who cared for these patients showed no evidence of alimentary infection. When the viruses were administered simultaneously, the type 1 virus alone produced antibodies unless type 2 was given first or in larger amounts. Mercurous chloride and other drugs intended to suppress fecal excretion of the virus had little effect. Administration of gamma globulin at the time the virus was ingested had no effect on the antibody response.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hilary Koprowski (1956) studied Poliomyelitis (n=225). Attenuated strains of poliomyelitis virus (SM type 1 or TN type 2) was evaluated on Antibody development. Administration of attenuated SM type 1 or TN type 2 poliomyelitis virus induced antibody development in 100% of 225 nonimmune subjects without causing acute disease or neurological manifestations.

synapsesocial.com/papers/6a92ac6b915bce628c4f5125https://doi.org/10.1001/jama.1956.02960460032008
Ask AI
Helpful
Bookmark
Share
View Full Paper